Antibody drug conjugates (ADCs) are attracting a tremendous amount of attention because they have the potential to revolutionize cancer treatment. Chemical ligation of cytotoxic agents to monoclonal antibodies allows the selective delivery of cytotoxins to tumor cells thereby potentially mitigating some of the damaging side-effects of cancer chemotherapy. There are currently nine FDA-approved ADCs and…
Bispecific antibodies are promising therapeutics for targeting cancer cells with high specificity.
Nanoparticle Tracking Analysis (NTA) with the Particle Metrix ZetaView® instrument family allows fast and reliable measurement of size, concentration, and Zeta Potential of nanoparticles. In contrast to scatter-based particle detection, fluorescence detection capability of the ZetaView® instrument allows the user to get biochemical information about particles. This increases the resolution and discriminatory power of the data. Furthermore,…
During an SPR experiment, there are many experimental parameters that must be controlled in order to optimize the performance of the system and to generate high-quality binding data. Of these parameters, minimizing non-specific binding (NSB) is one of the most imperative as it can directly affect the accuracy of your kinetic data.
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a global health concern. At the time of writing, the number of diagnosed cases around the world has exceeded 194 million with Asia recording over 60.5 million.
Recent breakthroughs with mRNA-based vaccines highlight the potential of lipid-based particles as powerful and versatile delivery vectors for vaccines and gene therapies. Used to measure particle size, stability, zeta potential and particle concentration, light scattering techniques are used extensively in the characterization of lipid nanoparticle and liposome research.
Quick, label-free methods with minimal sample prep for simultaneously measuring rAAV aggregation, capsid charge, and particle concentration.
With the maturation of monoclonal antibodies (mAbs) based cancer immunotherapy drugs that target specific, actionable biomarkers, the biopharmaceutical industry has been developing more complex mAbs, such as bispecific antibodies and antibody drug conjugates. The Business Research Company projects the global monoclonal antibody market will exceed USD 170 billion by 2025 at a 12.9 percent CAGR. And in Asia, several companies are leading the way with these advanced antibody drug pipelines, including Astellas and Daiichi Sankyo in Japan, Adpro in Korea, and Miracogen in China.
Lung cancer is one of the most common malignancies in the world, accounting for more than 1.6 million cases annually or twelve percent of all newly diagnosed cancers. It is also the leading cause of cancer deaths worldwide.
A leading research and development center for analytical and biological sciences in Singapore gains added flexibility and increased efficiency with Lauda’s latest hydro water bath solutions.
Delivering Growth – in Asia and Beyond.
© DKSH International Ltd.
Please enter your details here:
